Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

All-Trans-Retinoic Acid Treatment of IDH Mutant Astrocytes

ABSTRACT: All-Trans-Retinoic Acid Treatment of IDH Mutant Astrocytes

PROVIDER: PRJNA721930 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14237572.fastq.gz	Fastqsanger.gz
	SRR14237573.fastq.gz	Fastqsanger.gz
	SRR14237574.fastq.gz	Fastqsanger.gz
	SRR14237575.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

All-Trans-Retinoic Acid Treatment of IDH Mutant Astrocytes

Project description:All-Trans-Retinoic Acid Treatment of IDH Mutant Astrocytes

| PRJNA1061109 | ENA

Loss of retinoic acid signaling drives immune escape in IDH mutant gliomas

Project description:Gliomas are immunologically cold tumors that can be broken into several categories based on either RNA expression profiles or methylation profiles, with isocitrate dehydrogenase (IDH) mutations defining a major segregration between types. IDH mutant gliomas often exhibit defects in the retinoic acid pathway. We treated mice harboring IDH mutant gliomas with all-trans retinoic acid, and found that this treatment cause reductions in tumor growth and a swith in immune profiles in the tumor microenvironment.

2024-04-19 | GSE172387 | GEO

Gene expression changes in IDH mutant or IDH wildtype gliomas treated with All-trans Retinoic Acid

Project description:IDH mutant cells are deficient in retinoic acid production, which impacts downstream gene expression and pathways. We looked at the effect of supplementing IDH mutant glioma cells with ATRA on gene expression and downstream pathways. We compared gene expression changes with IDH WT cells that were also treated with ATRA

2019-12-11 | GSE141789 | GEO

All-Trans-Retinoic Acid Treatment of IDH Mutant Astrocytes

Project description:Immortalized human astrocytes were stably transfected to express IDH1 R132H. These cells were treated with 1uM ATRA

2024-04-01 | GSE252527 | GEO

All-Trans-Retinoic Acid Treatment of IDH Mutant Astrocytes

Project description:Immortalized human astrocytes were stably transfected to express IDH1 R132H. These cells were treated with 1uM ATRA

2021-04-15 | GSE172055 | GEO

Gene expression changes in IDH mutant or IDH wildtype gliomas treated with All-trans Retinoic Acid

Project description:Gene expression changes in IDH mutant or IDH wildtype gliomas treated with All-trans Retinoic Acid

| PRJNA594739 | ENA

Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

Project description:The main purpose of this clinical trial is to learn about the good and the bad effects of all trans retinoic acid (ATRA), atezolizumab and bevacizumab as a possible treatment for advanced colorectal patients. Participants will be treated with the following combination of these drugs: 1. ATRA will be given in a pill form to be taken twice a day at home for 7 days starting on day 1 of a cycle. 2. Atezolizumab will be given through a vein in arm or through mediport over 60-90 minutes every 2 weeks in the outpatient chemotherapy infusion centers at UTSW. 3. Bevacizumab will be given through a vein in arm or through mediport over 20-40 minutes every 2 weeks in the outpatient chemotherapy infusion centers at UTSW.

| 70824 | ecrin-mdr-crc

Loss of retinoic acid signaling drives immune escape in IDH mutant gliomas

Project description:Loss of retinoic acid signaling drives immune escape in IDH mutant gliomas

| PRJNA723194 | ENA

Gene expression changes in mouse neuroepithelial organoids in response to all-trans retinoic acid.

Project description:We describe the transcriptomic changes in neuroepithelial organoids in response to all-trans retinoic acid.

2022-10-01 | GSE214368 | GEO

RIME against PBX1 protein in P19.6 mouse embryonal carcinoma cells treated for 48 hours with all-trans retinoic acid

Project description:Identification of PBX1 interactors in P19.6 mouse embryonal carcinoma cells treated for 48 hours with all-trans retinoic acid.

2017-04-03 | PXD006158 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data